A5078606543- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- HER2/EGFR in Cancer Research
- Breast Lesions and Carcinomas
- Bladder and Urothelial Cancer Treatments
- Advanced Breast Cancer Therapies
- Molecular Biology Techniques and Applications
- Estrogen and related hormone effects
- Genetic factors in colorectal cancer
- Colorectal Cancer Treatments and Studies
- Gene expression and cancer classification
- BRCA gene mutations in cancer
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Cancer Treatment and Pharmacology
- Global Cancer Incidence and Screening
- Immunotherapy and Immune Responses
- Bioinformatics and Genomic Networks
- Prostate Cancer Treatment and Research
- Multiple and Secondary Primary Cancers
- Immune cells in cancer
- Cancer, Lipids, and Metabolism
- Ferroptosis and cancer prognosis
Exact Sciences (United States)
2020-2025
Genomic Health (United States)
2012-2023
University of Pittsburgh
2005-2023
University of California, San Francisco
2011-2023
Allegheny General Hospital
2006-2023
UCSF Helen Diller Family Comprehensive Cancer Center
2006-2022
Philipps University of Marburg
2020
University of Pittsburgh Medical Center
2017
NRG Oncology
2016-2017
Severance Hospital
2017
The likelihood of distant recurrence in patients with breast cancer who have no involved lymph nodes and estrogen-receptor-positive tumors is poorly defined by clinical histopathological measures.We tested whether the results a reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay 21 prospectively selected genes paraffin-embedded tumor tissue would correlate node-negative, tamoxifen-treated were enrolled National Surgical Adjuvant Breast Bowel Project trial B-14. levels expression...
Purpose The 21-gene recurrence score (RS) assay quantifies the likelihood of distant in women with estrogen receptor–positive, lymph node–negative breast cancer treated adjuvant tamoxifen. relationship between RS and chemotherapy benefit is not known. Methods was measured tumors from tamoxifen-treated tamoxifen plus chemotherapy–treated patients National Surgical Adjuvant Breast Bowel Project (NSABP) B20 trial. Cox proportional hazards models were utilized to test for interaction treatment...
Purpose To determine whether the Recurrence Score (RS) provided independent information on risk of distant recurrence (DR) in tamoxifen and anastrozole arms Arimidex, Tamoxifen, Alone or Combination (ATAC) Trial. Patients Methods RNA was extracted from 1,372 tumor blocks postmenopausal patients with hormone receptor–positive primary breast cancer monotherapy ATAC. Twenty-one genes were assessed by quantitative reverse transcriptase polymerase chain reaction, RS calculated. Cox proportional...
BackgroundFor women with ductal carcinoma in situ (DCIS) of the breast, risk developing an ipsilateral breast event (IBE; defined as local recurrence DCIS or invasive carcinoma) after surgical excision without radiation is not well by clinical and pathologic characteristics.
We developed quantitative gene expression assays to assess recurrence risk and benefits from chemotherapy in patients with stage II colon cancer.We sought validation by using RNA extracted fixed paraffin-embedded primary tumor blocks 1,436 cancer the QUASAR (Quick Simple Reliable) study of adjuvant fluoropyrimidine versus surgery alone. A score (RS) a treatment (TS) were calculated levels 13 cancer-related genes (n = 7 n 6 benefit genes) five reference prespecified algorithms. Cox...
Statins are cholesterol-lowering drugs with pleiotropic activities including inhibition of isoprenylation reactions and reduction signals driving cell proliferation survival responses. The objectives this study were to examine the effects statins on breast cancer cells, both in vitro vivo, begin determine their mechanism action. We evaluated growth, phosphoprotein signaling intermediates, survival/apoptosis regulators, cycle activated transcription factors. also examined vivo effect statin...
Adjuvant! is a standardized validated decision aid that projects outcomes in operable breast cancer based on classical clinicopathologic features and therapy. Genomic classifiers offer the potential to more accurately identify individuals who benefit from chemotherapy than features.A sample of 465 patients with hormone receptor (HR) -positive zero three positive axillary nodes did (n = 99) or not have recurrence after chemohormonal therapy had tumor tissue evaluated using 21-gene assay....
Abstract Current therapeutic approaches to cancer are designed target molecules that contribute malignant behavior but leave normal tissues intact. β1 integrin is a candidate well known for mediating cell-extracellular matrix (ECM) interactions influence diverse cellular functions; its aberrant expression has been implicated in breast progression and resistance cytotoxic therapy. The addition of inhibitory agents cells at single-cell stage laminin-rich ECM (three-dimensional lrECM) culture...
These studies were conducted to determine the relationship between quantitative tumor gene expression and risk of cancer recurrence in patients with stage II or III colon treated surgery alone plus fluorouracil (FU) leucovorin (LV) develop multigene algorithms quantify as well likelihood differential treatment benefit FU/LV adjuvant chemotherapy for individual patients.We performed reverse transcription polymerase chain reaction (RT-qPCR) on RNA extracted from fixed, paraffin-embedded (FPE)...
Multiple molecular signatures are available for managing estrogen receptor (ER)-positive breast cancer but with little direct comparative information to guide the patient's choice.
To determine the 12-year risk of developing an ipsilateral breast event (IBE) for women with ductal carcinoma in situ (DCIS) treated surgical excision (lumpectomy) without radiation.A prospective clinical trial was performed DCIS who were selected low-risk and pathologic characteristics. Patients enrolled onto one two study cohorts (not randomly assigned): cohort 1: low- or intermediate-grade DCIS, tumor size 2.5 cm smaller (n = 561); 2: high-grade 1 104). Protocol specifications included a...
<h3>Importance</h3> The presence of tumor-infiltrating lymphocytes at diagnosis is reported to be prognostic in triple-negative breast cancer. <h3>Objective</h3> To evaluate the association stromal (STILs) with recurrence-free survival (RFS) women human epidermal growth factor receptor 2 (HER2)–positive cancer treated chemotherapy or plus trastuzumab N9831 trial. <h3>Design, Setting, and Participants</h3> Hematoxylin-eosin–stained tumor slides from patients early-stage HER2-positive 3 arms...
Validated biomarkers are needed to improve risk assessment and treatment decision-making for women with ductal carcinoma in situ (DCIS) of the breast. The Oncotype DX® DCIS Score (DS) was shown predict local recurrence (LR) individuals low-risk treated by breast-conserving surgery (BCS) alone. Our objective confirm these results a larger population-based cohort individuals. We used an established diagnosed BCS alone from 1994 2003 validation outcomes. Central pathology excluded cases...
PURPOSE The 21-gene recurrence score (RS) assay quantifies the likelihood of distant in women with estrogen receptor–positive, lymph node–negative breast cancer treated adjuvant tamoxifen. relationship between RS and chemotherapy benefit is not known. METHODS was measured tumors from tamoxifen-treated tamoxifen plus chemotherapy–treated patients National Surgical Adjuvant Breast Bowel Project (NSABP) B20 trial. Cox proportional hazards models were utilized to test for interaction treatment...
To our knowledge, WSG-ADAPT-HR+/HER2- (ClinicalTrials.gov identifier: NCT01779206; n = 5,625 registered) is the first trial combining 21-gene expression assay (recurrence score [RS]) and response to 3-week preoperative endocrine therapy (ET) guide systemic in early breast cancer.Baseline postendocrine Ki67 (Ki67post) were evaluated centrally. In trial, all patients received exclusively ET: with pathologic regional lymph node status (pN) 0-1 (ie, 0-3 involved nodes) entered control arm if RS...
Abstract Models of bladder tumor progression have suggested that genetic alterations may determine both phenotype and clinical course. We applied expression microarray analysis to a divergent set tumors further elucidate the course disease classify into more homogeneous clinically relevant subgroups. cDNA microarrays containing 10,368 human gene elements were used characterize global patterns in 80 tumors, 9 cancer cell lines, 3 normal samples. Robust statistical approaches accounting for...
Central and local laboratory concordance for hormone receptor measurement is therapeutically important. This study compares estrogen (ER) progesterone (PR) measured by immunohistochemistry (IHC), central IHC, reverse-transcriptase polymerase chain reaction (RT-PCR) using a proprietary 21-gene assay.